Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, Safety, and Tolerability of Tirzepatide Solution in Healthy Subjects
NCT03375463Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2017
- Primary completion
- Dec 2018
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tirzepatide in type 2 diabetes mellitus (T2DM) and obesity (6 arms), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration Versus Time Curve [AUC (0-∞)] of Tirzepatide and Maximum Observed Drug Concentration (Cmax) of Tirzepatide. Started Dec 2017; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT03375463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03375463.